OCULIS HOLDING AG Share Price Today: Live Updates & Key Insights

OCULIS HOLDING AG share price today is $24.81, up -2.01%. The stock opened at $25.48 against the previous close of $25.37, with an intraday high of $26 and low of $24.55.

OCULIS HOLDING AG Share Price Chart

OCULIS HOLDING AG

us-stock
To Invest in {{usstockname}}
us-stock

OCULIS HOLDING AG Share Price Performance

$24.81 -0.0201(-2.01%) OCS at 23 Mar 2026 02:34 PM Biotechnology
Lowest Today 24.55
Highest Today 26
Today’s Open 25.48
Prev. Close 25.37
52 Week High 30.68
52 Week Low 14.00
Day’s Range: Low 24.55 High 26
52-Week Range: Low 14.00 High 30.68
1 day return -
1 Week return -4.92
1 month return -13.74
3 month return +21.7
6 month return +43.07
1 year return +26.3
3 year return +139.16
5 year return +154.94
10 year return -

OCULIS HOLDING AG Institutional Holdings

OCULIS HOLDING AG Market Status

Strong Buy: 5

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

OCULIS HOLDING AG Fundamentals

Market Cap 1441.49 M

PB Ratio 5.8907

PE Ratio 0.0

Enterprise Value 1202.71 M

Total Assets 236.23 M

Volume 282053

OCULIS HOLDING AG Company Financials

Annual Revenue FY23:null 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M

Annual Net worth FY23:null 0.0M, FY22:-38698000 -38.7M, FY21:-18552000 -18.6M, FY20:-14873000 -14.9M

Quarterly Revenue Q3/2025:243000 0.2M, Q2/2025:261000 0.3M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:245000 0.2M

Quarterly Profit Q3/2025:243000 0.2M, Q2/2025:-14648000 -14.6M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:-16220000 -16.2M

Quarterly Net worth Q3/2025:-16855000 -16.9M, Q2/2025:-25375000 -25.4M, Q1/2025:-33213000 -33.2M, Q3/2024:-20190000 -20.2M, Q2/2024:-20839000 -20.8M

About OCULIS HOLDING AG & investment objective

Company Information Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.

Organisation Biotechnology

Employees 49

Industry Biotechnology

CEO Dr. Riad Sherif M.B.A., M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

OCULIS HOLDING AG FAQs

What is the share price of OCULIS HOLDING AG today?

The current share price of OCULIS HOLDING AG is $24.81.

Can I buy OCULIS HOLDING AG shares in India?

Yes, Indian investors can buy OCULIS HOLDING AG shares by opening an international trading and demat account with Motilal Oswal.

How to buy OCULIS HOLDING AG shares in India?

You can easily invest in OCULIS HOLDING AG shares from India by:

Can I buy fractional shares of OCULIS HOLDING AG?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of OCULIS HOLDING AG?

OCULIS HOLDING AG has a market cap of $1441.49 M.

In which sector does OCULIS HOLDING AG belong?

OCULIS HOLDING AG operates in the Biotechnology sector.

What documents are required to invest in OCULIS HOLDING AG stocks?

To invest, you typically need:

What is the PE and PB ratio of OCULIS HOLDING AG?

The PE ratio of OCULIS HOLDING AG is N/A and the PB ratio is 5.89.